高级检索
当前位置: 首页 > 详情页

Burden of Lung Cancer in China, 1990-2019: Findings from the Global Burden of Disease Study 2019

文献详情

资源类型:
Pubmed体系:
机构: [1]Institute of Cancer Prevention and Treatment, Harbin Medical University, Harbin City, People's Republic of China. [2]Key Laboratory of Cardiovascular Disease Acousto-Optic Electromagnetic Diagnosis and Treatment in Heilongjiang Province, The First Affiliated Hospital, Harbin Medical University, Harbin City, People's Republic of China. [3]Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin City, People's Republic of China. [4]Department of Pathology, Harbin Medical University Cancer Hospital, Harbin City, People's Republic of China. [5]Colorectal Surgery, Harbin Medical University Cancer Hospital, Harbin City, People's Republic of China. [6]Department of Radiology, Chengdu Second People's Hospital, Chengdu City, People's Republic of China. [7]Pelvic Floor Disease Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu City, People's Republic of China.
出处:
ISSN:

关键词: lung cancer death incidence prevalence epidemiology

摘要:
Lung cancer is one of the most common malignant tumors in the world. It has become an increasingly important public health problem in China. In this study, we systematically assessed the lung cancer situation in China from 1990 to 2019 and provided an epidemiological knowledge base for the revision of health policies. The relevant data were extracted from the Global Burden of Disease (GBD) database.Based on GBD 2019 data, we evaluated the incidence, prevalence, and death rates of lung cancer in China and their change trends from 1990 to 2019, making comparisons by gender and age.The age-standardized incidence and death rates (ASIR and ASDR, respectively) of lung cancer in China were higher than the average levels in Asia, Africa, Europe, and Oceania and also higher than those of neighboring Asian countries. Lung cancer rose from the seventh leading cause of death in 1990 to the fourth leading one in 2019, indicating that the disease burden of lung cancer is increasing. In 2019, the incidence, prevalence, and death rates of lung cancer were all higher in men than in women across all age groups. All three indices were lower in men and women <50 years old than in men and women >50 years. From 1990 to 2019, the ASIR, age-standardized prevalence rate (ASPR), and ASDR showed trends of increase (P < .05), and the rise in the ASPR (average annual percentage change [AAPC] = 1.9) was greater than those in the ASIR (AAPC = 1) and ASDR (AAPC = .8).From 1990 to 2019, the incidence, prevalence, and death rates of lung cancer continued to increase in China. To reduce this burden, prevention and management of known risk factors should be promoted through national policies.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
第一作者:
第一作者机构: [1]Institute of Cancer Prevention and Treatment, Harbin Medical University, Harbin City, People's Republic of China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号